ArticleBreast cancer research and treatment2024
Development of a core outcome set for breast cancer-related lymphedema: a Delphi study.
Article in Breast cancer research and treatment, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Microsurgical versus complex physical decongestive therapy for chronic breast cancer-related lymphoedema.The Cochrane database of systematic reviews · 2025Pooled it
- Effectiveness of complete decongestive therapy for upper extremity breast cancer-related lymphedema: a review of systematic reviews.Medical oncology (Northwood, London, England) · 2024Pooled it
- Clinician Perspectives on Implementing Breast Cancer-Related Lymphedema Prospective Screening.JAMA network open · 2026Article
- Breast cancer-related lymphedema of the upper limb: integrating early surveillance and functional surgery into a synergistic management paradigm.Frontiers in surgery · 2026Review
- Effects of 4-Week Complex Decongestive Therapy in the Management of Breast Cancer-Related Arm Lymphedema in Montenegrin Women Post-Mastectomy and Chemo/Radiotherapy.Healthcare (Basel, Switzerland) · 2025Article
- The effect of compression therapies and therapeutic modalities on lymphedema secondary to cancer: a rapid review and evidence map.Medical oncology (Northwood, London, England) · 2024Review
- An expert perspective on diversity-oriented standards for assessing sex and gender in clinical research.Frontiers in psychiatry · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeFor breast cancer survivors (BCS) living with breast cancer-related lymphedema (BCRL), what outcome domains (OD) should be measured to assess the burden of the disease and efficacy of interventions? A Core Outcome Set (COS) that promotes standardized measurement of outcomes within the constraints of time influenced by work environments is essential for patients and the multidisciplinary professionals that manage and research BCRL.
methodsUsing Delphi methodology, a multidisciplinary group of BCRL experts (physical and occupational therapists, physicians, researchers, physical therapist assistants, nurses, and massage therapist) completed two waves of online surveys. BCRL expert respondents that completed the first survey (n = 78) had an average of 26.5 years in practice, whereas, respondents who completed the second survey (n = 33) had an average of 24.9 years. ODs were included in the COS when consensus thresholds, ranging from 70% to 80%, were met.
resultsA total of 12 ODs made up the COS. Reaching a minimum consensus of 70%; volume, tissue consistency, pain, patient-reported upper quadrant function, patient-reported health-related quality of life, and upper extremity activity and motor control were recommended at different phases of the BCRL continuum in a time-constrained environment. Joint function, flexibility, strength, sensation, mobility and balance, and fatigue met an 80% consensus to be added when time and resources were not constrained.
conclusionThe COS developed in this study thoroughly captures the burden of BCRL. Using this COS may reduce selective reporting, inconsistency in clinical use, and variability of reporting across interdisciplinary healthcare fields, which manage or research BCRL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.